NBIX vs. NVO: Neurocrine Biosciences vs. Novo Nordisk Stock Comparison

Company Profile

Neurocrine Biosciences (NBIX) and Novo Nordisk (NVO) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but NBIX is classified in Biotechnology while NVO is classified in Pharmaceuticals.

Neurocrine Biosciences (NBIX) trades as ordinary local shares, while Novo Nordisk (NVO) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Both Neurocrine Biosciences (NBIX) at 20.42% and Novo Nordisk (NVO) at 58.38% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.

Both Neurocrine Biosciences (NBIX) at 18.98% and Novo Nordisk (NVO) at 33.92% keep an unusually large share of revenue as bottom-line profit — each net margin clears its industry’s benchmark range.

Both Neurocrine Biosciences (NBIX) at 31.98% and Novo Nordisk (NVO) at 40.05% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Both Neurocrine Biosciences (NBIX) at 21.45% and Novo Nordisk (NVO) at 6.43% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Both Neurocrine Biosciences (NBIX) at 41.95% and Novo Nordisk (NVO) at 1.77% land near their industries' usual EPS growth ranges, so bottom-line momentum looks broadly in line with peers on both sides.

Growth Metrics

Financial Strength

Both Neurocrine Biosciences (NBIX) at 2.04 and Novo Nordisk (NVO) at 0.85 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

Both Neurocrine Biosciences (NBIX) at 0.12 and Novo Nordisk (NVO) at 0.62 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

Financial Strength Metrics

Dividends

Neurocrine Biosciences (NBIX) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Novo Nordisk (NVO) reports a yield of 29.03%, ranking against industry peers normally.

Neurocrine Biosciences (NBIX) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Novo Nordisk (NVO) reports a payout of 45.36%, ranking against industry peers normally.

Dividend Metrics

Valuation

Novo Nordisk (NVO) at 10.18 sits in the cheaper P/E ratio quartile, while Neurocrine Biosciences (NBIX) at 24.43 is closer to its industry’s usual earnings multiple — a discount for NVO, though growth and earnings durability still matter.

Novo Nordisk (NVO) at 0.53 sits in the cheaper P/S ratio quartile while Neurocrine Biosciences (NBIX) at 4.50 prices around its industry’s middle — NVO costs less per dollar of sales, though read it alongside growth and margins.

On P/B ratio, both Neurocrine Biosciences (NBIX) at 4.30 and Novo Nordisk (NVO) at 5.43 are valued close to their industries’ norm against book — neither stands out from peers.

Valuation Metrics